Frazier Closes $600M Fund; VCs Say Bio Interest 'Robust'
By Donna Young
Thursday, November 29, 2007
Although venture capital investing in the biotechnology arena slowed in the third quarter of 2007, with fewer deals completed and dollars invested than in the two previous quarters, the space continues to have strong interest for VC firms, said Mark Heesen, president of the National Venture Capital Association. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.